GlassScriptPhysician profile
Pedro A Mego
NPI 1982675740
$23,210.46
in general payments reported to CMS, 2019-2025
28 companies · $2,069 in 2025
The $2,069 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,228 · 2021: $1,501 · 2022: $1,107 · 2023: $2,273 · 2024: $1,063 · 2025: $2,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,234 · Travel and Lodging: $2,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,234.01 |
| Travel and Lodging | $2,169.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $10,113.27 | 2019-2024 | Lutonix Drug Coated Balloon |
| Philips North America LLC | $4,335.69 | 2019-2025 | Igt Devices Undivided, IV Other, (Dd1) Duo Hybrid |
| Boston Scientific Corporation | $1,991.13 | 2019-2025 | Varithena Administration Pack |
| Cardiovascular Systems INC. | $1,691.97 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $837.91 | 2020-2022 | |
| Medtronic, INC. | $798.91 | 2022-2025 | Corevalve Evolut R, Hawkone |
| Tactile Systems Technology INC | $672.60 | 2021-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Novartis Pharmaceuticals Corporation | $284.09 | 2023-2025 | |
| Pfizer INC. | $265.34 | 2019-2024 | |
| Terumo Medical Corporation | $250.00 | 2019 | |
| Amgen INC. | $205.75 | 2019-2024 | Repatha |
| Cardinal Health 200 LLC | $202.16 | 2020-2021 | |
| Melinta Therapeutics, LLC | $174.11 | 2023-2025 | Kimyrsa |
| Abiomed | $168.51 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $166.44 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sechrist Industries INC | $154.77 | 2024 | |
| Medtronic Vascular, INC. | $141.09 | 2019 | |
| Averitas Pharma INC. | $128.57 | 2024-2025 | Qutenza |
| Biotronik INC. | $121.63 | 2021 | |
| Veryan Medical Incorporated | $114.27 | 2023 | Biomimics 3d Vascular Stent System |
| Novo Nordisk INC | $93.90 | 2023-2025 | Wegovy |
| Abbott Laboratories | $81.18 | 2019-2023 | Diamondback Peripheral |
| Abbvie INC. | $72.45 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $43.46 | 2020-2023 | Eliquis |
| Angiodynamics, INC. | $43.14 | 2025 | Auryon Laser System 100-120 Vac |
| Celonova Biosciences, INC. | $26.09 | 2020 | |
| Cook Medical LLC | $18.42 | 2022 | |
| Esperion Therapeutics, INC. | $13.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Mego listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.